Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1403716 | 0.83 | ALDH1A1 (0.47) | ALDH1A1USP2HPGDCA2SMN1; SMN2 | |
| SCHEMBL27450326 | 0.82 | TNKS2 (0.43) | TNKS2ALDH1A1TSHRSIRT2USP2 | |
| SCHEMBL334409 | 0.77 | CNR1 (0.41) | TNKS2ALDH1A1TSHRSIRT2USP2 | |
| SCHEMBL13667239 | 0.77 | MAOB (0.49) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1423103 | 0.77 | TNKS2 (0.42) | TNKS2ALDH1A1TSHRSIRT2USP2 | |
| SCHEMBL28785864 | 0.75 | TNKS2 (0.38) | TNKS2ALDH1A1TSHRSIRT2USP2 | |
| SCHEMBL334184 | 0.75 | TNKS2 (0.41) | TNKS2ALDH1A1TSHRSIRT2USP2 | |
| SCHEMBL1067152 | 0.75 | SIRT2 (0.47) | ALDH1A1TSHRSIRT2SMN1; SMN2CHRM5 | |
| SCHEMBL5775345 | 0.73 | ALDH1A1 (0.44) | ALDH1A1TSHRHPGDRAD52SMN1; SMN2 | |
| SCHEMBL13150548 | 0.73 | TNKS2 (0.37) | TNKS2ALDH1A1TSHRSIRT2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118094-B1 | GAMMA-LACTAMS FOR THE TREATMENT OF GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | claimed |
| EP-2114875-B1 | SUBSTITUTED ARYLCYLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2012-08-15 | — | — | EP | claimed |
| EP-2114875-A1 | SUBSTITUTED ARYLCYLOPENTENES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008091810-A1 | SUBSTITUTED ARYLCYLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-31 | — | — | WO | claimed |
| EP-2118094-B1 | GAMMA-LACTAMS FOR THE TREATMENT OF GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8362054-B2 | Therapeutic substituted lactams | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2114875-B1 | SUBSTITUTED ARYLCYLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2297085-A2 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100168189-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. | 2010-07-01 | — | — | US | disclosed |
| EP-2114875-A1 | SUBSTITUTED ARYLCYLOPENTENES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009132093-A2 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2008091810-A1 | SUBSTITUTED ARYLCYLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168189-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | PIGO, GARS1, CLPP | TNKS2 2260/4885ALDH1A1 2303/4885TSHR 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.